Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria + tetanus + acellular pertussis + haemophilus influenzae type b combined vaccine
- Development stage
- Phase 1
- Lead developer
- Zhifei Biological
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The **diphtheria + tetanus + acellular pertussis + haemophilus influenzae type b combined vaccine** (DTaP-Hib) is an investigational tetravalent combination vaccine developed by **Beijing Zhifei Lvzhu Biopharmaceutical**, a subsidiary of Chongqing Zhifei Biological Products. This biologic product is designed to provide active immunization against four major pediatric pathogens: *Corynebacterium diphtheriae*, *Clostridium tetani*, *Bordetella pertussis*, and *Haemophilus influenzae* type b (Hib). The vaccine formulation typically includes diphtheria and tetanus toxoids, acellular pertussis antigens (such as pertussis toxoid and filamentous hemagglutinin), and a purified Hib capsular polysaccharide conjugated to a carrier protein, all adsorbed onto an aluminum hydroxide adjuvant to enhance immunogenicity. It is currently being evaluated in Phase I clinical trials in China (e.g., CTR20260906) to assess its safety, tolerability, and immunogenicity in infants, toddlers, and children, often using the approved pentavalent vaccine Pentaxim as an active comparator.
- Other names
- DTaP-Hib combined vaccineAdsorbed acellular diphtheria-tetanus-pertussis and Haemophilus influenzae type b combined vaccineDTaP-Hib vaccine
02
Targets
Diphtheria toxin
Beyond the preview
Go deeper on diphtheria + tetanus + acellular pertussis + haemophilus influenzae type b combined vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria + tetanus + acellular pertussis + haemophilus influenzae type b combined vaccine.